3-[2-(1,3-benzodioxol-5-yl)-2-oxoethylidene]-5-bromo-1H-indol-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 3-[2-(1,3-benzodioxol-5-yl)-2-oxoethylidene]-5-bromo-1H-indol-2-one
• 化学式: C₁₇H₁₀BrNO₄
• 分子量: 372.2
• InChiKey: CJHSOCYXEPXZJP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Methods and compositions relating to steroid hormone receptor-dependent cancers
  申请人：Wayne State University

  公开号：US11185527B2

  公开（公告）日：2021-11-30

  There is a continuing need for methods and compositions relating to hormone-receptor-dependent cancers, including pharmaceutical compositions including one or more compounds having activity against steroid hormone-receptor-dependent cancer and methods of treatment of a steroid hormone-receptor-dependent cancer in a subject using said pharmaceutical compositions. ELK1 is a steroid hormone receptor tethering, protein that is implicated in hormone receptor dependent cancers. Compositions and methods according to aspects of the present invention inhibit the association of steroid hormone receptors with ELK1 providing activity against steroid hormone-receptor-dependent cancer. Such compositions are provided including any one or more of: chemical compound structures I, II, III, IV, V, VI, VII, one or more derivatives, and/or one or more: pharmaceutically acceptable esters and/or one or more pharmaceutically acceptable salts, of any thereof, wherein a pharmaceutically acceptable carrier may be included in the compositions.

  目前仍然需要与激素受体依赖性癌症有关的方法和组合物，包括对类固醇激素受体依赖性癌症有活性的一种或多种化合物的药物组合物，以及使用所述药物组合物治疗受试者的类固醇激素受体依赖性癌症的方法。ELK1是一种类固醇激素受体拴系蛋白，与激素受体依赖性癌症有关。根据本发明各方面的组合物和方法可抑制类固醇激素受体与 ELK1 的结合，从而提供抗类固醇激素受体依赖性癌症的活性。所提供的此类组合物包括：化合物结构 I、II、III、IV、V、VI、VII 中的任意一种或多种，一种或多种衍生物，和/或一种或多种：其中任意一种的药学上可接受的酯和/或一种或多种药学上可接受的盐，其中组合物中可包括药学上可接受的载体。
• METHODS AND COMPOSITIONS RELATING TO STEROID HORMONE RECEPTOR-DEPENDENT CANCERS
  申请人：Wayne State University

  公开号：US20200155501A1

  公开（公告）日：2020-05-21

  There is a continuing need for methods and compositions relating to hormone-receptor-dependent cancers, including pharmaceutical compositions including one or more compounds having activity against steroid hormone-receptor-dependent cancer and methods of treatment of a steroid hormone-receptor-dependent cancer in a subject using said pharmaceutical compositions. ELK1 Is a steroid hormone receptor tethering, protein that is implicated in hormone receptor dependent cancers. Compositions and methods according to aspects of the present invention inhibit the association of steroid hormone receptors with ELKL providing activity against steroid hormone-receptor-dependent cancer. Such compositions are provided including any one or more of: chemical compound structures I, II, III, IV, V, Vi, VII, one or more derivatives, and/or one or more: pharmaceutically acceptable esters and/or one or more pharmaceutically acceptable salts, of any thereof, wherein a pharmaceutically acceptable carrier may be included in the compositions.